Search PubMed⌕ Search

PubMed · 3706316

Achieving excellence.

Abstract

The concept of achieving excellence in pharmacy through development of effective leadership is discussed. The majority of hospital pharmacy directors have had very little education and training in management and effective leadership. Yet, excellent leadership skills will be needed to transform pharmacy more completely into a health profession. The management style most likely to be effective in this era of change is one that encompasses a high regard for both people and production through shared responsibility, high participation, involvement, and commitment. The following recommendations are offered to help achieve excellence through effective leadership: the ethic of self-development must be instilled in aspiring managers; courses in human behavior, leadership, and management should be added to undergraduate pharmacy curricula; pharmacy technicians should be educated in college-based programs that focus on drug distribution; Master of Science programs in hospital pharmacy should be deleted or restructured to focus on leadership and management; regional "centers for excellence" in leadership education should be developed; general residency training should be incorporated in undergraduate education so that more advanced residencies can be offered to graduates; high-level, self-study programs in management and leadership need to be developed, and substantial research funds need to be dedicated to the study of hospital pharmacy management.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R B Williams. 1986. Achieving excellence.. https://pubmed.ncbi.nlm.nih.gov/3706316/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Evaluation of two commercial kits for the detection of genotypic drug resistance on a panel of HIV type 1 subtypes A through J.

We compared the two commercially available sequencing kits for HIV-1 drug resistance testing, the ViroSeq Genotyping System (Applied Biosystems, Foster City, CA, U.S.A.) and the TRUGENE HIV-1 Genotyping Kit (Visible Genetics, Inc., Toronto, Ontario, Canada), with our in-house genotyping system. Fifteen viral isolates from African patients (6 treated and 9 untreated) covering a panel of HIV-1 subtypes A through J and 7 plasma samples from Belgian and African patients (2 treated and 5 untreated) were tested. All the samples could be amplified and sequenced by the three systems; however, for all systems, alternative amplification/sequencing primers had to be used for some samples belonging to subtype B as well as to other subtypes. The consensus sequence was partially derived from only one strand for the in-house system and for the ViroSeq Genotyping System. The TRUGENE HIV-1 Genotyping Kit scored the highest number of ambiguities, followed by the ViroSeq Genotyping System and the in-house system. For 11 samples, these differences in reporting mixtures affected 14 resistance-related positions, which altered the interpretation toward protease inhibitors for 2 samples when using version 1.2 RetroGram software (Virology Networks, Utrecht, The Netherlands). All three systems were able to sequence diluted samples with a viral load down to 10 3 or 10 4 RNA copies/ml. Our data therefore suggest that the performance of amplification and sequencing primers must be improved to allow fast and reliable resistance testing for all HIV-1 subtypes.

Drug Industry↗